RxDoctor Payments Data

David Sass, MD

Gastroenterology · Philadelphia, PANPI 1730154774

Payments from drug & device makers

$144,940in general payments, 2019–2025

Across 43 payments — averaging $3370.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$95K
  • Ipsen Pharma SAS$36K
  • Mallinckrodt Hospital Products Inc.$7K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$5K
  • Mallinckrodt Enterprises LLC$2K
  • Fujifilm Healthcare Americas Corporation$281
  • plus $112 from 6 others

What the payments were for

  • Speaking & faculty fees$4,50088%
  • Food & beverage$61212%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$144,940 in reported general payments places this provider in the 90th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$62,877
Medicare patients
302
Services billed
550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin93$306,609
OcalivaObeticholic Acid17$196,996
VemlidyTenofovir Alafenamide85$130,402
RezdiffraResmetirom18$103,713
Tacrolimus272$48,831
Sirolimus42$26,683
Ursodiol173$25,079
Envarsus XrTacrolimus25$19,807
Entecavir50$19,423
Tenofovir Disoproxil Fumarate65$6,842
Mycophenolate Mofetil53$4,434
Cyclosporine ModifiedCyclosporine, Modified12$3,265
Nadolol21$2,951
Pantoprazole Sodium140$1,683
Mycophenolic AcidMycophenolate Sodium11$1,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$4,500$306,60993 claims
GileadVemlidy$94,667$130,40285 claims
Madrigal PharmaceuticalsRezdiffra$14$103,71318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →